Barclays PLC Takes Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Barclays PLC purchased a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,616 shares of the company’s stock, valued at approximately $304,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $42,000. MetLife Investment Management LLC acquired a new stake in Artiva Biotherapeutics in the third quarter valued at $135,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth $623,000. Acuta Capital Partners LLC acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $680,000. Finally, State Street Corp acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $1,337,000.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $6.53 on Tuesday. The stock has a 50-day simple moving average of $10.61. Artiva Biotherapeutics, Inc. has a 52 week low of $6.50 and a 52 week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Analysts forecast that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ARTV. HC Wainwright started coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.